Buoy fractionation system

Information

  • Patent Grant
  • 8596470
  • Patent Number
    8,596,470
  • Date Filed
    Monday, February 20, 2012
    12 years ago
  • Date Issued
    Tuesday, December 3, 2013
    10 years ago
Abstract
A separator system operable to use centrifugation to fractionate a multiple component material, such as a suspension including blood, comprises a buoy. The buoy can be carried in a separation container and has a tuned density that is configured to reach an equilibrium position in the multiple component material. A guide surface is carried on a buoy upper surface and is inclined to an accumulation position near a buoy perimeter. The buoy suspension fractionation system can be used in a method of isolating a fraction from a suspension, and in a method for re-suspending particulates for withdrawal.
Description
FIELD

The present teachings relate to a separator that uses density differences to fractionate a suspension such as blood.


BACKGROUND

Clinicians have identified a wide range of therapeutic and laboratory applications for autologous isolated fractions, such as platelet concentrate, platelet-poor-plasma, and stromal cells, of suspensions such as blood, bone marrow aspirate, and adipose tissue. Clinicians generally prefer to draw and fractionate the autologous suspension at the point-of-care. Point-of-care fractionation can reduce the need for multiple appointments to draw and fractionate the autologous suspension which can be costly and inconvenient. Additionally, point-of-care preparation reduces potential degradation of the autologous suspension that can begin once the autologous suspension is removed from a patient. Point-of-care fractionation systems should be easy to operate to reduce the need to provide clinicians with extensive instruction, quick so the therapeutic fraction can be isolated and administered during a single patient visit, efficient to effectively isolate the fraction to a desired concentration, and reproducible to operate over wide variations in suspension characteristics. An example of a buoy based suspension fractionation system is shown in Biomet Biologics, Inc. international brochure entitled “Gravitational Platelet Separation System Accelerating the Body's Natural Healing Process,” 2006.


SUMMARY

A buoy suspension fractionation system comprises a separation container and a buoy. The separation container defines a volume enclosed by a container wall, a container bottom, a container top and an access port to access the volume. The buoy is carried in the separation container and has a tuned density that is configured to reach an equilibrium position in a suspension. The buoy comprises a buoy upper surface and a buoy sidewall defining a height, a transverse dimension, and a perimeter. The buoy further comprises a guide surface and a collection space above the buoy upper surface. The guide surface is carried on the buoy upper surface and is inclined to an accumulation position near the buoy perimeter. The buoy suspension fractionation system can be used in a method of isolating a fraction from a suspension, and in a method for isolating a fraction and re-suspending isolated particulates for withdrawal.





BRIEF DESCRIPTION OF THE DRAWINGS

The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:



FIG. 1 is an environmental view of a fractionation device including a suspension fractionated during the centrifuge process;



FIG. 2 is an environmental view of a suspension being added to a fractionation device;



FIG. 3 is an environmental view of a centrifuge;



FIG. 4 is an environmental view of a first fraction being removed from the fractionation device;



FIG. 5. is an environmental view of the fractionation device being agitated to re-suspend a portion in a second fraction;



FIG. 6 is an environmental view of the second fraction being removed from the fractionation device;



FIG. 7 is an environmental view of a therapeutic application of the second fraction;



FIG. 8 is an environmental view of a separation container and a buoy;



FIG. 9A is a plan view of a buoy according to various embodiments;


FIG. 9A1 is a plan view of a buoy at a selected transverse plane;


FIG. 9A2 is a plan view of a buoy at a selected transverse plane;



FIG. 9B is a cross-sectional view of the buoy of FIG. 2A;



FIG. 10 is a perspective view of a buoy, according to various embodiments;



FIG. 11A is a perspective view of a buoy, according to various embodiments;



FIG. 11B is a perspective view of a buoy in a closed position, according to various embodiments;



FIG. 12 is a perspective view of a buoy, according to various embodiments;



FIG. 13 is a perspective view of a buoy, according to various embodiments;



FIG. 14 is a plan view of a buoy, according to various embodiments;



FIG. 15 is a plan view of a buoy, according to various embodiments;



FIG. 16. is a plan view of a buoy, according to various embodiments;



FIG. 17 is a plan view of a buoy, according to various embodiments;



FIG. 18 is a plan view of a buoy, according to various embodiments;



FIG. 19 is an environmental view of a selected component being withdrawn from a separation device according to various embodiments; and



FIG. 20 is a kit according to various embodiments, for separation and extraction of a selected component of a suspension.





DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS


FIG. 1 shows a buoy suspension fractionation system 10, according to various embodiments that can be used in a clinical or laboratory environment to isolate fractions from a suspension or multi-component material removed from a patient or a preparation of extracted or excised material from a patient. The suspension can include a sample of blood, bone marrow aspirate, cerebrospinal fluid, adipose tissue, and the isolated fractions can include platelets, platelet poor plasma, platelet rich plasma and stromal cells. The isolated fractions can each have equilibrium point or positions within the separation container that are achieved when separation has occurred. For example, a buffy coat of whole blood may have an equilibrium position above that of the red blood cells when a sample of whole blood is separated.


Isolated fractions can be used in a variety of clinical applications, animal applications, and laboratory applications. Some of the clinical applications include peripheral vascular disease, orthopedic surgery, plastic surgery, oral surgery, cardio-thoracic surgery, brain and neural procedures, and wound healing. Laboratory applications include isolating, creating or synthesizing therapeutic materials or materials for analysis from fractions produced by the fractionation system.


Although the fractionation system 10 can be used allogeneically, such as with pooled blood, the fractionation system 10 can be used autologously to reduce risks of potential incompatibility and contamination with pathogenic diseases. Also, other autologous materials can be used including cerebrospinal fluid, cerebrospinal fluid can be obtained via a spinal tap or other appropriate collection procedure. A general description of a fractionation system is provided in a Biomet Biologics, Inc. international brochure “Gravitation Platelet Separation System Accelerating the Body's Natural Healing Process” (2006) and a description of a therapeutic procedure using platelet concentrate is shown in a Biomet Biologics, Inc. international brochure “Shoulder Recovery with the GPS® Platelet Concentration System” (2004), incorporated herein by reference.



FIGS. 2-7 show exemplary fractionation system operational steps for a clinical therapeutic application embodiment. The operational steps begin in FIG. 2 by inputting autologous (although pooled blood can be used) whole blood into the fractionation system 10, via an access port 22. The fractionation system 10 is placed into a centrifuge 23 in FIG. 3 and spun about five minutes to about twenty minutes at a rate of about 320 rpm to about 5000 rpm (this speed may produce a selected gravity that may be approximately 7.17×g to about 1750×g (times greater than the normal force of gravity)). The first fraction or top fraction 308 (FIG. 1), which can be platelet-poor-plasma according to various embodiments including from a whole blood sample, is shown being removed in FIG. 4. The fractionation system 10 is agitated in FIG. 5 to re-suspend at least a portion of a second fraction 310, which can be platelet-rich-plasma or platelet concentrate, according to various embodiments including from whole blood fractionation. The second fraction is removed from the fractionation system 10 in FIG. 6. Finally, the second fraction is applied as part of a therapy, such as shown in FIG. 7 to treat elbow tendonitis. The second fraction can be injected into a selected portion of an elbow 29 to treat tendonitis.


It will be understood that the buoy 30 can be altered depending upon the material placed in the container 12. For example, if neural stem cells are to be separated from cerebrospinal fluid then the buoy 30 can have a density to allow collection of the neural stem cells in the collection area 52 of the system 12. The collected neural stem cells can also be applied for therapeutic reasons or used in laboratory study, isolation, culture, etc.


Returning reference to FIG. 1 and with additional reference to FIGS. 8-9B, the suspension fractionation system 10 comprises a separation container 12 and a buoy 30. The separation container 12 can be a separation tube having a container wall 16, a container bottom 18, and a container top 20 enclosing a volume 21 that can be accessed by one or more access ports 22, 26, 27, and a container vent 31. The container 12 may be formed of any appropriate material, such as the Cryolite Med® 2 material sold by Cyro Industries Evonik Degussa Corp. The container 12 can be about 50 mm to about 150 mm in height, including about 102 mm in height. The container 12 can have an internal diameter of about 20 mm to about 40 mm, including about 25 mm to about 35 mm and define a volume of about 30 ml to about 100 ml, including about 30 ml to about 60 ml. The separation container 12 can have any appropriate shape, such as an oval, provided the buoy 30 is shaped to conform to the separation container 12. Though not particularly illustrated, the separation container 12 can also have more than one compartment, such as a separation tube and an area to transfer tube contents away from the separation tube 12. For example, a separate compartment can be formed to house the assembly of the buoy 30 and isolator 32 separate from another area.


The various ports 22, 26 and 27 can be provided to allow access to any appropriate compartment of the container 12. The access ports 22, 26, 27 can be any means that allow communication from outside the separation container 12 to the separation container volume 21 such as a Luer lock port, a septum, a valve, or other opening. The container vent 31 allows movement of air between the inside and outside the separation container 12 to equalize pressure when suspension in introduced into or withdrawn from the separation container 12. The container vent 31 can include a vent filter 31a to serve as a sterile barrier to allow air to enter the separation container 12 while preventing undesired materials from entering the separation container 12.


When the separation container 12 is at rest, a buoy perimeter 30a and the container wall 16 can be dimensioned to form an interference fit to hold the buoy 30 at a position in the separation container 12. When the separation container 12 is centrifuged, the buoy perimeter 30a and the container wall 16 have clearance allowing the buoy 30 to move within the separation container 12 and a material to pass between the buoy perimeter 30a and the container wall 16. For example, the container 12 can compress axially to increase its internal diameter. Alternatively, the buoy 30 could have an opening (e.g. FIG. 16), such as a centrally or internally located opening 176 or a peripheral channel 168a (FIG. 13) running the height of the buoy, which would allow a material to move through the buoy.


The buoy 30 is carried in the separation container 12 and has a tuned density that is configured to reach a selected equilibrium position in a suspension. The buoy can have its density tuned in the range from about 1.0 g/cc to about 1.10 g/cc, such as about 1.06 g/cc. The buoy 30, according to various embodiments, can be formed to include the tuned density and can be formed of one or more materials to achieve the tuned density.


For example, the density of about 1.06 g/cc can position the buoy 30, or a selected part of the buoy 30 including the collection area 52, at an equilibrium position of a buffy coat of a separated whole blood sample. In a further example, the density can also be tuned so that the collection area 52 is near an equilibrium position, such as where neural stem cells collect in a selected suspension. Regardless of the density of the buoy 30, it can be selected to position the buoy 30 at an equilibrium position of a selected material.


As illustrated in FIG. 1, the collection area 52 is positioned within the container 12 after a separation procedure has occurred. The collection area, defined relative to the buoy 30, is positioned at the equilibrium position of the separated or isolated fraction 310 in the container. The equilibrium position of a selected fraction can be defined as its position within the container relative to other fractions in the container of a separated sample or material. The equilibrium position can also be defined relative to the axis X of the buoy 30 or the container 12. The equilibrium position, however, may depend upon the amount of the sample of the amount of a selected fraction within a sample. According to the illustration in FIG. 1, the equilibrium position of the fraction 308 is above or nearer the top 20 of the container 12 than the equilibrium position of the fraction 310. Thus, the buoy 30 can be tuned, such as including a selected density or specific gravity, to position the collection area 52 relative to an equilibrium position of any selected fraction.


The buoy comprises a buoy upper surface 48 and a buoy sidewall 38, 40 defining a height H1, H2, a transverse dimension at planes A1, A2, and a perimeter 30a, discussed further herein. The buoy further comprises a guide surface 42. In some embodiments, the buoy can further comprise a collection port 50 and a precision collection region 44. The collection port 50 communicates with the access port 27 and communicates with a collection space 52 above the buoy upper surface 42 and can be located near the buoy perimeter 30a. In some embodiments, the collection port 50 is not carried on the buoy, but rather the collection port is a withdraw device such as a syringe that is inserted through an access port or top of the tube 12.


With reference to FIG. 9A, the buoy 30 has a first height dimension H1, a second height dimension H2, a maximum width or transverse cross sectional area W1 at plane A1, a second width or transverse cross sectional area W2 at plane A2, a guide surface angle α, and precision collection area 44 including a surface 46 defining a precision collection region angle β. The height of the buoy 30, according to various embodiments, can be defined relative to a central axis X, which can also be a longitudinal axis X of the container 12. The sidewalls of the buoy 30 and the container 12 can also be substantially parallel to the axis X. Although certain dimensions are shown in FIG. 9A, the buoy perimeter could be shaped differently provided the perimeter conforms to the separation container 12.


The guide surface 42 is carried on and/or defined by the buoy upper surface 48 and is inclined to an accumulation position at or near the buoy perimeter. The guide surface 42 serves as a guide means for conveying particles down an incline toward an equilibrium interface or collection region. The guide surface 42 can be inclined relative to the buoy sidewall 38 height for a distance of more than one-half the buoy transverse dimension or width W1, such as about two-thirds the buoy transverse dimension, and in various embodiments the guide surface can be inclined relative to the buoy sidewall 38 substantially throughout a length of the guide surface 42.


The guide surface 42 can be substantially planar and can have an average angle in the range from the minimum for particulates to move down the guide surface, regarding blood platelets, for example, about 10 degrees to about 60 degrees. For example, angle custom character can be about 5 degrees to about 89 degrees, or greater, including about 30 degrees to about 89 degrees. Angle custom character can, exemplary, be exactly or about 60 degrees in various embodiments. In some embodiments, the guide surface can include contours defined in the guide surface with multiple angles such as shown in FIGS. 10 and 12. For example, in FIG. 10, a buoy 80, according to various embodiments, can include two guide surface contour walls 96, 98 to assist in defining a guide surface 100. The two walls 96, 98 can define a trough that extends a selected distance across the guide surface 100, such as more than two thirds. The trough can define an area of the guide surface that is lower than the surrounding area. A contoured precision collection region 92 can also be defined that communicates with a port 94. In FIG. 12, a buoy 140 can include a guide surface 152 that includes two inclined sides 154, 156 angled towards a selected region, such as a center of the guide surface 152. The entire guide surface can also be inclined towards a collection port 158, in an amount as discussed above.


In various embodiments, as exemplary illustrated in FIGS. 9A, 9A1, and 9A2 the different buoy transverse cross-sectional areas W1, W2 can be defined at various planes, such as A1, A2, etc. As illustrated, various transverse cross-sectional areas can be defined by the buoy 30 due to the angled top wall 42. The transverse cross-sectional areas defined at the various planes A1, A2 can be positioned at selected locations based upon characteristics of the buoy 30, such as density. The height H2, angle custom character, etc. The width dimension can be 1 inch to about 2 inches including about 1.347 inches (about 25 mm to about 51 mm, including about 34.21 mm) for W2. The dimension of W1 can depend upon the selected location of plane A1. These dimensions can achieve various areas depending upon the geometry of the buoy 30. Nevertheless, the area at plane A2 can be substantially similar to an area at a transverse plane within the container 12.


In use, the substantially maximum transverse cross-sectional area W1 of the buoy 30 can be positioned at a selected location. As illustrated in FIG. 9A1, the maximum cross-sectional area is at plane A1. The plane A1 can be positioned at or near a selected equilibrium interface, in use. The position of the plane A1 is selected by selecting a density of the buoy 30 and the known or estimated density of the material into which the buoy 30 is positioned. The buoy's maximum transverse cross-sectional area near the intended or selected interface results in a substantially maximum change in displacement of the relative volume of a fraction below the equilibrium interface and substantially maximum change in displacement of a fraction above the equilibrium interface relative to change in the axial orientation of the buoy relative to the interface. This can improve fractionation isolation by ensuring that the maximum transverse cross-section displaces a maximum amount of area within the container 12 at the selected interface. For example, more than 90% of a whole blood's platelets can be isolated.


Thus, in applications involving suspensions, such as whole blood, which may be variable in composition between samples, sample density variation will result in minimal variation in the axial orientation of the buoy relative to a selected equilibrium interface. The minimal variation in axial location of the buoy 30 in the container 12 is based at least in part on the maximum displacement of a material in the container at the maximum transverse cross-section of the buoy 30. In other words, for each small variation of axial location of the buoy 30, a maximum displacement occurs. In selected uses, the buoy's maximum cross-sectional plane A1 is provided at a selected location and the minimal axial variation helps to ensure the plane A1 is properly placed.


Additionally, at or near the buoy's maximum transverse cross-sectional area, the cross-sectional area of the fractionated material is near minimal. Simply, within the container 12 at a selected position if a maximum transverse cross-section of the buoy 30 is at a selected position, then a relatively minimal amount of other material can be present at the same location. In combination, the minimization of cross-sectional area of fractionated material and minimization of variation of axial orientation of the buoy in relation to an equilibrium interface results in minimization of variability of fractionated material volume near the interface.


The precision collection region 44, 92 (FIGS. 9A, 9B, and 10) can be interposed between the guide surface and the accumulation position at or near the buoy perimeter. The precision collection region 44, 92 serves as a precision collection structure for collecting a precise, high yield and/or pure amount of a selected fraction. The precision collection region 44, 92 can be raised or lowered in relation to the buoy perimeter to vary the fraction in the collection region without the need to make substantial changes to other buoy design features. In other words, the dimension H1 can be changed. Generally, the height H2 can be about 2.5 mm to about 5.1 mm. The height H1 will generally be constrained by the height H2 and the angle custom character. According to various embodiments, the precision collection region 44 is shown in FIG. 9A formed at an angle β in relation to the sidewall 40. The angle β can be any appropriate angle such as about 10 degrees to about 60 degrees, including about 45 degrees. According to various embodiments, the precisions collection region 92 can be contoured, FIG. 10.


According to various embodiments, an isolator 32, is coupled to the buoy 30. The combination of the isolator and buoy, according to various embodiments, can also be referred to as a separation assembly member. Exemplary isolators 82, 122, 170, 180, 190 are illustrated coupled to exemplary buoys 80, 120, 140, 160, 182, 192. The isolator 32, for example, provides a means for creating the collection compartment 52 and comprises one or more spacers 58, 60 to position the isolator 32 apart from the buoy 30 to create the collection compartment 52. A withdraw port 70 can be carried on the isolator 32 communicating with the withdraw port 27 and the collection port 50. The spacer 58, 60 can also serve as a conduit 68 between the collection port 50 and a withdraw or withdraw port 27. The withdraw port 27 serves as a structure for withdrawing the isolated or second fraction 310 from the collection compartment 52.


The isolator 32 can be configured from a material with a lower density than the buoy 30, such as a density of about 1.0 g/cc or less. A volume of the isolator 32 can be substantially less than a volume of the buoy 30. The isolator 32 can be configured so the isolator volume and the buoy volume combined below a selected equilibrium interface are greater than the isolator volume and the buoy volume combined above the equilibrium interface. As discussed above, an equilibrium interface can include a position relative to the platelet concentrate or buffy coat from a centrifuged whole blood sample, such as at or just below the platelet concentrate or buffy coat. By configuring the isolator 32 and buoy 30 with more volume below the equilibrium interface than above the equilibrium interface, the buoy 30 operates in a more repeatable manner even between a wide range in variations in compositions such as whole blood where the variability in density of a more dense fraction (e.g. red blood cells) is less than the variability in density of a less dense fraction (e.g. plasma). For example, the make up of a whole blood sample from one patient to the next can be markedly different.


Between individual patients, the density of the red blood cell or erythrocyte fraction of a whole blood sample can generally vary less than the density of a plasma or serum portion of a whole blood sample. Therefore, positioning a greater volume of the isolator and buoy within the denser fraction can assist in having highly repeatable and highly efficient collection or separation of a whole blood sample. The height H2 can be varied or selected to ensure a maximum or selected volume of the isolator and buoy are positioned within the denser fraction of the whole blood sample.


According to various embodiments, the isolator may include various features. An isolator 122 can be configured to move relative to a buoy 120, as illustrated in FIGS. 11A and 11B. The isolator 122 can move along a column or spacer 132 in the direction of arrow 123 during extraction of a selected fraction. The isolator 32, 82 can also be substantially uniformly thick or vary in thickness 122, 180, 190.


An isolator 170 can include collection openings 174 (FIG. 13). The isolator 32 can also include a collection vent 67 (FIG. 9A), which can also include a collection valve, a collection passage, or a collection vent tube or passage 203. The collection openings 174 can reduce the distance particles, such as platelets which are fragile and adherent, travel to reach a guide surface 162 and reduce the time that particles are in contact with surfaces. Various types of collection openings can be used.


The collection openings 174 can be sized to permit selected particles to pass yet sufficiently small so suspension fluid tension maintains adequate isolation of the collection compartment. The collection openings can also include various valves such as a duck bill or flapper bill which can open under certain conditions and close under others. A collection valve can be interconnected with any appropriate portion such as with a collection port 70 or passage 68.


The collection vent passage 67 through the isolator 32 equalizes pressure when fluid is withdrawn from the collection area 52. The spacer 58 can serve as a conduit for the collection vent passage 67, the collection port 50, or both. The collection valve communicates with the collection vent passage 67 to control collection vent passage 67 operation and close the collection vent passage 67 during re-suspension agitation. The collection vent tube 203 communicates with the collection vent passage 67 and air. The air can be the air above the collection area 52 (i.e. a portion of the suspension above the isolator 32 has been removed) or through an opening 205 in the container wall and generally through a sterile barrier (e.g. a sterile foam filter). The collection vent tube 203 allows removal of fractionated suspension in the collection compartment without the need to remove the fraction, such as plasma, above the isolator 32. Although, without a collection vent tube 203, the fraction above the isolator could be removed and the collection area could be vented to the area above the isolator.


Various embodiments further comprise a mechanical agitator 130 carried in a collection compartment 128 (for example FIGS. 11A and 11B).


The isolator 122 is moveable relative to the buoy 120. The isolator 122 can be in an open position after centrifugation of the separation container. During removal of material from the collection compartment through the collection port 134, the isolator 122 can move in the direction indicated by arrow 123 toward the buoy 120 to decrease or close the volume of the collection compartment 128.


The buoy 30 can also be formed in a plurality of selectable sizes, having different dimensions, such as those illustrated in FIG. 9A. The axial dimensions of the buoy 30 can be selected to achieve an appropriate displacement of the suspension in the container 12, especially after fractionation has occurred. Angle α, defined between the outer edge 38 and the surface 42 can be any selected angle. For example, angle α can be about 30 degrees to about 89 degrees, including about 60 degrees. The angle α can generally be created to be as small as possible to allow a steep angle of the surface 42 towards the inlet port 50 that will not damage the material being collected within the collection space 52. As discussed above, the height H2 can be selected to determine or select the amount of the buoy 30 positioned within a selected fraction, such as a dense fraction, of a sample separated within the separation system. Height H2 can be about 0.1 inches to about 0.2 inches, including about 0.18 inches (about 2.5 mm to about 5.1 mm, including about 4.57 mm). An exemplary height H2 is 0.1795 inches (4.559 mm), depending upon selected applications, the size of the separation system, and other selected factors. Nevertheless, the height H1 is generally defined by the height H2 and the angle α. Height H1 can be about 0.8 inches to about 1.2 inches, including about 1 inch (about 20 mm to about 30 mm, including about 25 mm). An exemplary height H1 can include 1.0 inches (25 mm). The positioning of the collection area 52, including the inlet port 50, can be based upon the height H2 and how the buoy 30 interacts with the material into which it is positioned, via the height H2.


A buoy 182, as illustrated in FIG. 17, can include an isolator 180 positioned relative thereto. The isolator 180 can include a center placed substantially over a center of the buoy 182. The center of the buoy 182 and the isolator 182 can both be defined by peaks or apexes 184 and 186, respectively.


A buoy 192, as illustrated in FIG. 18, can also be positioned relative to an isolator 190. The buoy 192 can include an apex 194 near a center of the buoy 192 and the guide surface extending from an edge of the buoy 192 to a second edge of the buoy 192. The isolator 190 can also include an apex 196 generally near its center. The isolator 190 can also include a surface 198 that extends from one edge of the isolator to another edge of the isolator 190.


The isolators 180, 190 can act substantially similar to the isolator 32, discussed above. The isolator 180, 190 can define an angle between an apex or the withdrawal port 70 and an outer edge of the isolators 180, 190. The upper surface of the isolators can include an angle to assist in directing a selected material, such as a platelet fraction of whole blood sample, to the collection area or surface 42 of the buoys 182, 192. Generally, the isolators 180, 190 can include a height or volume to substantially minimize the volume of the isolator 180, 190 relative to the buoys 182, 192. As discussed above, this can assist in positioning the buoys 182, 192 relative to a dense (e.g. red blood cell) fraction of a whole blood sample. The angle of the isolators 180, 190 and the height of the isolators 180, 190 can be selected to provide for a minimal distance of travel or least disturbance of a selected collected fraction of a material, such as a whole blood sample.


As discussed above, the buoy suspension fractionation system 10 can be used in a method of isolating a fraction from a suspension. The separation container 12 can be centrifuged for a period that is appropriate for the suspension. The buoy 30 in the separation container 12 is allowed to reach an equilibrium position within the formed fractions. Typically, the buoy moves from the separation container bottom to an equilibrium position within and/or between the fractions. In some embodiments, the buoy 30 is configured with the transverse dimension cross-sectional area of the buoy near the equilibrium interface to be substantially the buoy's maximum transverse cross-sectional area A1, as illustrated in FIG. 1. As discussed above, the design of the buoy can be determined to position a maximum cross sectional area of the buoy within a selected fraction, such as the red blood cell fraction, of a whole blood sample. The positioning of the buoy can be based upon the density of the buoy which is determined from the density of a selected fraction, such as a red blood cell fraction. Therefore, the buoy can be created or formed to include a density to substantially position it within a red blood cell fraction, for example, of a sample to be separated. For example, the buoy can have a density of about 1.010 g/cc to about 1.1 g/cc. Exemplary densities include about 1.058 g/cc to about 1.070 g/cc, including about 1.064 g/cc. Such a buoy design effects a substantially maximum change in displacement of a volume of fractionated suspension below an equilibrium interface and effects a substantially maximum change in displacement of a volume of fractionated suspension above the equilibrium interface relative to the axial displacement of the buoy resulting in more precisely controlling the selected fraction isolation. As discussed above, the buoy, according to various embodiments, has a maximum cross section at a selected region. Positioning a maximum cross section within a selected fraction or area of a sample will maximum displacement of the sample relative to the buoy do to the maximum cross section of the buoy. In other words, by positioning the biggest portion of the buoy within a selected sample the biggest portion of the sample is displaced because of the displacement of the buoy.


Particulates are concentrated using a guide surface 42, 90, 138, 152, 162 of the buoy that is inclined to an accumulation position near a perimeter of the buoy. The guide surface can be inclined relative to the buoy sidewall substantially throughout a length of the guide surface. The guide surface can be defined by or positioned near the top wall of the buoy.


The particulates are conveyed along the guide surface of the buoy to a collection space. The particulates can be conveyed along a substantially planar path to the collection space. According to various embodiments, however, the guide surface can also include multiple angles 42, 44 and 152, 154 and/or contours 96, 98. The particulates can be selected from the group consisting of platelets, stromal cells, white blood cells, or the like.


A desired fraction is withdrawn from the collection space through an access port. In some embodiments, the desired fraction can be withdrawn from the collection space by tipping the separation container and pouring the desired fraction out through an access port or out through the container top. This is especially true when only the buoy 30′, 30″, 30″′ is present (FIGS. 14, 15, and 16).


In some embodiments, the method of isolating a fraction can further comprise isolating an isolated fraction in a collection compartment between the guide surface of the buoy 30, 80, 120, 140, 160, 180, 190 and an isolator 32, 82, 122, 142, 162, 182, 192 coupled to the buoy and withdrawing the isolated fraction through a withdraw port through the isolator.


The buoy suspension fractionation system can be used in a method of isolating and re-suspending particulates for withdrawal. The method begins by filling a separation container through an access port with a suspension. The separation container has a buoy with a tuned density and the suspension can contact the buoy.


The separation container can be centrifuged to cause the suspension to separate into fractions of varying densities. Centrifugation can occur for a period that is appropriate for the suspension, such as about five to about thirty minutes.


The buoy in the separation container is allowed to reach equilibrium within the fluid between two or more fractions. Typically the buoy moves from the separation container bottom to equilibrium within the fractions. In some embodiments, particulates can be concentrated using a guide surface of the buoy. The guide surface can be inclined to an accumulation position 44, 92 near a buoy perimeter location. According to various embodiments, the guide surface can be inclined relative to a buoy sidewall substantially throughout the length of the guide surface. The particulates can be conveyed along the guide surface of the buoy to a collection port. The particulates can be platelets, stromal cells, white blood cells, or the like.


A fraction is isolated in a collection compartment between the guide surface of the buoy and an isolator coupled to the buoy. In some embodiments, there can be a fraction 308 located above the isolator that can be withdrawn prior to withdrawing a first increment of the second fraction 310. In other embodiments, the collection vent tube 203 can eliminate the need to withdraw the fraction 308 located above the isolator prior to withdrawing the first increment of the second fraction 310.


Particulates within the isolated fraction can be re-suspended within the collection compartment by moving an agitator 130, 316 (FIGS. 11A and 19) in the separation container 12 to agitate the isolated fraction to create a more uniform particulate distribution within the isolated fraction. In some embodiments, the agitator is an air bubble 316 that is created by withdrawing the first increment of the isolated fraction 310 from a collection compartment allowing air to enter the collection compartment through the collection vent 58. In other embodiments, the agitator 130 is a mechanical agitator placed in the collection compartment.


The re-suspended isolated fraction can be withdrawn from the collection compartment.


For illustration and for efficiency of use of the system, the various components can be included in a kit 320, illustrated in FIG. 20. The kit 320 includes the fractionation system 10 and a counterweight container 322 if required for centrifuge balance. The kit 320 can also include various syringes 302, 312, and 314 for extraction and application of the fractions and samples. The kit 320 can also include bandages 3226, tape 330, a tourniquet 328, and various additive materials. The kit 320 can include a container 332 for transport and sterilization.


Thus, embodiments of a buoy suspension fractionation system are disclosed. One skilled in the art will appreciate that the teachings can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the invention is only limited by the claims that follow.

Claims
  • 1. A buoy fractionation system, comprising: a buoy member having a first surface and an opposed second surface defining a width of the buoy member at an outer perimeter of the buoy member;wherein at least the first surface extends to the outer perimeter of the buoy member and transverse to an axis extending from the second surface;wherein the first surface has a surface portion that is angled toward a sump region that is nearer the outer perimeter than a center of the buoy member;wherein the first surface is angled toward the sump region for greater than one-half of the width of the buoy member;wherein the at least a portion of the buoy member is configured to be moved to an interface of at least two fractions of a separated material and the sump region is configured to positioned within one of the two fractions;wherein an angled portion of the first surface extends through the center of the buoy member to the sump region;wherein the first surface includes a precision collection area having an angle towards the sump region that is different from the angle of the surface portion of the first surface.
  • 2. The buoy fractionation system of claim 1, wherein the first surface is angled from a first edge of the perimeter to a second edge of the perimeter, wherein the second edge is opposite the first edge.
  • 3. The buoy fractionation system of claim 1, wherein the buoy member further defines a through passage that extends entirely through the buoy member and the first surface and the second surface such that a material is operable to pass the buoy member through the through passage.
  • 4. The buoy fractionation system of claim 1, wherein the first surface is planar and is a guide surface configured to guide at least a portion of a multiple component material to the sump region.
  • 5. The buoy fractionation system of claim 4, further comprising: a container having a first end spaced apart from a second end;wherein the first surface of the buoy member is directly accessible from at least one of the first end of the container or the second end of the container.
  • 6. The buoy fractionation system of claim 1, further comprising: a container having a first end wall configured to have a centrifugal force applied thereto to separate components of a multiple component material;wherein the second surface is configured to move away from the first end wall.
  • 7. A buoy fractionation system, comprising: a buoy member having a first surface and an opposed second surface defining a width of the buoy member at an outer perimeter of the buoy member; anda container having a first end spaced apart along an axis from a second end;wherein the first surface of the buoy member is directly accessible from at least one of the first end of the container or the second end of the container;wherein at least the first surface extends to the outer perimeter of the buoy member;wherein the first surface is angled relative to the axis;wherein a sump region is nearer the outer perimeter than a center of the buoy member;wherein the first surface has a surface portion that is angled toward the sump region for greater than one-half of the width of the buoy member;wherein the at least a portion of the buoy member is configured to be moved to an interface of at least two fractions of a separated material and the sump region is configured to positioned within one of the two fractions;wherein an angled portion of the first surface extends through the center of the buoy member to the sump region;wherein the first surface includes a precision collection area having an angle towards the sump region that is different from the angle of the surface portion of the first surface.
  • 8. The buoy fractionation system of claim 7, wherein the first surface extends an entire width of the buoy member and is angled from a first edge of the perimeter to a second edge of the perimeter, wherein the second edge is opposite the first edge through the center of the buoy member.
  • 9. The buoy fractionation system of claim 8, wherein the surface portion of the first surface is a planar guide surface configured to guide at least a portion of a multiple component material to the sump region.
  • 10. The buoy fractionation system of claim 7, wherein the buoy member further defines a tapered through passage that extends entirely through the buoy member and the first surface and the second surface such that a material is operable to pass the buoy member through the through passage.
  • 11. The buoy fractionation system of claim 7, wherein the second surface is configured to move away from the first end wall.
  • 12. The buoy fractionation system of claim 11, wherein the second surface is convex.
  • 13. A buoy fractionation system, comprising: a buoy member having a first guide surface and an opposed second surface defining a width of the buoy member at an outer perimeter of the buoy member; anda container having a first end spaced apart along an axis from a second end and configured to receive the buoy member where the outer perimeter of the buoy member is configured to slidably engage an inner wall surface of the container;wherein the first guide surface of the buoy member is accessible directly from at least one of the first end or the second end of the container;wherein the first guide surface extends to the outer perimeter of the buoy member;wherein the first guide surface is angled relative to the axis of the container when positioned within the container;wherein the first guide surface is angled greater than one-half the width of the buoy member;wherein at least a portion of the buoy member is configured to be moved to an interface of at least two fractions of a separated material wherein at least a portion of the first guide surface is configured to be positioned within one of the two fractions,wherein an angled portion of the first guide surface has a surface portion that extends through a center of the buoy member towards the outer perimeter;wherein the first guide surface includes a precision collection area that has an angle towards the outer perimeter that is different from the angle of the first guide surface.
  • 14. The buoy fractionation system of claim 13, wherein the first guide surface extends an entire width of the buoy member and is angled from a first edge of the perimeter to a second edge of the perimeter, wherein the second edge is opposite the first edge through the center of the buoy member.
  • 15. The buoy fractionation system of claim 13, wherein the buoy member further defines a tapered through passage that extends entirely through the buoy member and the first guide surface and the second surface such that a material is operable to pass the buoy member through the through passage.
  • 16. The buoy fractionation system of claim 13, wherein the second surface is convex.
  • 17. The buoy fractionation system of claim 13, wherein the first guide surface is angled at least two-thirds the width of the buoy member.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/897,401 filed on Oct. 4, 2010, now U.S. Pat. No. 8,119,013, which is a divisional of U.S. patent application Ser. No. 12/101,594 filed on Apr. 11, 2008, now U.S. Pat. No. 7,806,276 issued on Oct. 5, 2010, which claims the benefit of U.S. Provisional Application No. 60/911,407 filed on Apr. 12, 2007. The disclosures of the above applications and patents are incorporated herein by reference.

US Referenced Citations (486)
Number Name Date Kind
280820 Hickson et al. Jul 1883 A
593333 Park Nov 1897 A
1468313 Lux Sep 1923 A
1593814 Vogel Jul 1926 A
2722257 Lockhart Nov 1955 A
3013557 Pallotta Dec 1961 A
3159159 Cohen Dec 1964 A
3409165 Creith Nov 1968 A
3441143 Kudlaty Apr 1969 A
3453364 Flodin et al. Jul 1969 A
3469369 Helmke Sep 1969 A
3508653 Coleman Apr 1970 A
3545671 Ross Dec 1970 A
3583627 Wilson Jun 1971 A
3596652 Winkelman Aug 1971 A
3654925 Holderith Apr 1972 A
3706305 Berger et al. Dec 1972 A
3706306 Berger et al. Dec 1972 A
3723244 Breillatt, Jr. Mar 1973 A
3779383 Ayres Dec 1973 A
3785549 Latham, Jr. Jan 1974 A
3814248 Lawhead Jun 1974 A
3849072 Ayres Nov 1974 A
3850369 Bull et al. Nov 1974 A
3879295 Glover et al. Apr 1975 A
3887466 Ayres Jun 1975 A
3894952 Ayres Jul 1975 A
3896733 Rosenberg Jul 1975 A
3897337 Ayres Jul 1975 A
3897343 Ayres Jul 1975 A
3909419 Ayres Sep 1975 A
3929646 Adler Dec 1975 A
3931010 Ayres et al. Jan 1976 A
3931018 North, Jr. Jan 1976 A
3935113 Ayres Jan 1976 A
3937211 Merten Feb 1976 A
3941699 Ayres Mar 1976 A
3945928 Ayres Mar 1976 A
3951801 Ayres Apr 1976 A
3957654 Ayres May 1976 A
3962085 Liston et al. Jun 1976 A
3965889 Sachs Jun 1976 A
3972812 Gresl, Jr. Aug 1976 A
3982691 Schlutz Sep 1976 A
4001122 Griffin Jan 1977 A
4020831 Adler May 1977 A
4046699 Zine, Jr. Sep 1977 A
4055501 Cornell Oct 1977 A
4059108 Latham, Jr. Nov 1977 A
4066549 Oeser et al. Jan 1978 A
4077396 Wardlaw et al. Mar 1978 A
4088582 Murty et al. May 1978 A
4146172 Cullis et al. Mar 1979 A
4152270 Cornell May 1979 A
4154690 Ballies et al. May 1979 A
4159896 Levine et al. Jul 1979 A
4187979 Cullis et al. Feb 1980 A
4203840 Stoeppler et al. May 1980 A
4204537 Latham, Jr. May 1980 A
4225580 Rothman et al. Sep 1980 A
4269718 Persidsky May 1981 A
4294707 Ikeda et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300717 Latham, Jr. Nov 1981 A
4303193 Latham, Jr. Dec 1981 A
4314823 Rich, Jr. et al. Feb 1982 A
4322298 Persidsky Mar 1982 A
4362567 Schwarz et al. Dec 1982 A
4364832 Ballies et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4379849 Heimreid Apr 1983 A
4411794 Schwinn et al. Oct 1983 A
4414976 Schwarz et al. Nov 1983 A
4416654 Schoendorfer et al. Nov 1983 A
4417981 Nugent Nov 1983 A
4424132 Iriguchi et al. Jan 1984 A
4427650 Stroetmann et al. Jan 1984 A
4427651 Stroetmann et al. Jan 1984 A
4442655 Stroetmann et al. Apr 1984 A
4443345 Wells Apr 1984 A
4446021 Aufderhaar et al. May 1984 A
4453927 Sinko Jun 1984 A
4453939 Zimmerman et al. Jun 1984 A
4464167 Schoendorfer et al. Aug 1984 A
4511662 Baran et al. Apr 1985 A
4537767 Rothman et al. Aug 1985 A
RE32089 Blatt et al. Mar 1986 E
4577514 Bradley et al. Mar 1986 A
4610656 Mortensen Sep 1986 A
4617009 Ohlin et al. Oct 1986 A
4627879 Rose et al. Dec 1986 A
4631055 Redl et al. Dec 1986 A
4632761 Bowers et al. Dec 1986 A
4639316 Eldegheidy Jan 1987 A
4650678 Fuhge et al. Mar 1987 A
4655211 Sakamoto et al. Apr 1987 A
4672969 Dew Jun 1987 A
4675117 Neumann et al. Jun 1987 A
4680025 Kruger et al. Jul 1987 A
4714457 Alterbaum Dec 1987 A
4735616 Eibl et al. Apr 1988 A
4735726 Duggins Apr 1988 A
4755300 Fischel et al. Jul 1988 A
4755301 Bowers Jul 1988 A
4770779 Ichikawa et al. Sep 1988 A
4776964 Schoendorfer et al. Oct 1988 A
4818291 Iwatsuki et al. Apr 1989 A
4818386 Burns Apr 1989 A
4828710 Itoh et al. May 1989 A
4832851 Bowers et al. May 1989 A
4844818 Smith Jul 1989 A
4846835 Grande Jul 1989 A
4850952 Figdor et al. Jul 1989 A
4853137 Ersson et al. Aug 1989 A
4871462 Fischel et al. Oct 1989 A
4874368 Miller et al. Oct 1989 A
4877520 Burns Oct 1989 A
4879031 Panzani et al. Nov 1989 A
4902281 Avoy Feb 1990 A
4909251 Seelich et al. Mar 1990 A
4915847 Dillon et al. Apr 1990 A
4917801 Luderer et al. Apr 1990 A
4928603 Rose et al. May 1990 A
4929242 Desecki et al. May 1990 A
4939081 Figdor et al. Jul 1990 A
4943273 Pages et al. Jul 1990 A
4946601 Fiehler Aug 1990 A
4957637 Cornell Sep 1990 A
4957638 Smith Sep 1990 A
4983157 Pober et al. Jan 1991 A
4983158 Headley Jan 1991 A
4985153 Kuroda et al. Jan 1991 A
5000970 Shanbhag et al. Mar 1991 A
5002571 O'Donnell, Jr. et al. Mar 1991 A
5019243 McEwen et al. May 1991 A
5024613 Vasconcellos et al. Jun 1991 A
5030215 Morse et al. Jul 1991 A
5030341 McEwen et al. Jul 1991 A
5039401 Columbus et al. Aug 1991 A
5045048 Kaleskas et al. Sep 1991 A
5047004 Wells Sep 1991 A
5053127 Schoendorfer et al. Oct 1991 A
5053134 Luderer et al. Oct 1991 A
5071570 Shiraki et al. Dec 1991 A
5080262 Herold et al. Jan 1992 A
5086784 Levine et al. Feb 1992 A
5100564 Pall et al. Mar 1992 A
5104375 Wolf et al. Apr 1992 A
5112484 Zuk, Jr. May 1992 A
5112490 Turpen May 1992 A
5131907 Williams et al. Jul 1992 A
5137832 Levine et al. Aug 1992 A
5141645 Shiraki et al. Aug 1992 A
5147290 Jonsson et al. Sep 1992 A
5152905 Pall et al. Oct 1992 A
5156613 Sawyer Oct 1992 A
5165938 Knighton Nov 1992 A
5171456 Hwang et al. Dec 1992 A
5173295 Wehling et al. Dec 1992 A
5178602 Wells Jan 1993 A
5185001 Galanakis Feb 1993 A
5190057 Sarfarazi Mar 1993 A
5190759 Lindblad et al. Mar 1993 A
5197985 Caplan et al. Mar 1993 A
5203825 Haynes et al. Apr 1993 A
5204537 Bennet et al. Apr 1993 A
5206023 Hunziker et al. Apr 1993 A
5207638 Choksi et al. May 1993 A
5217426 Bacehowski et al. Jun 1993 A
5217627 Pall et al. Jun 1993 A
5219328 Morse et al. Jun 1993 A
5226877 Epstein Jul 1993 A
5226914 Caplan et al. Jul 1993 A
5234608 Duff Aug 1993 A
5236604 Fiehler Aug 1993 A
5251786 Sarrine Oct 1993 A
5258126 Pall et al. Nov 1993 A
5260420 Burnouf-Radosevich et al. Nov 1993 A
5269927 Fiehler Dec 1993 A
5271852 Luoma, II Dec 1993 A
5279825 Wehling et al. Jan 1994 A
5281342 Biesel et al. Jan 1994 A
5290552 Sierra et al. Mar 1994 A
5290918 Bui-Khac et al. Mar 1994 A
5298171 Biesel et al. Mar 1994 A
5304372 Michalski et al. Apr 1994 A
5316674 Pall et al. May 1994 A
5318524 Morse et al. Jun 1994 A
5318782 Weis-Fogh et al. Jun 1994 A
5321126 van Dommelen et al. Jun 1994 A
5322620 Brown et al. Jun 1994 A
5330974 Pines et al. Jul 1994 A
5344752 Murphy Sep 1994 A
5354483 Furse Oct 1994 A
5370802 Brown Dec 1994 A
5372945 Alchas et al. Dec 1994 A
5376263 Fischel Dec 1994 A
5387187 Fell et al. Feb 1995 A
5393674 Levine et al. Feb 1995 A
5395923 Bui-Khac et al. Mar 1995 A
5403272 Deniega et al. Apr 1995 A
5405607 Epstein Apr 1995 A
5409833 Hu et al. Apr 1995 A
5411885 Marx May 1995 A
5417650 Gordon May 1995 A
5420250 Lontz May 1995 A
5443481 Lee Aug 1995 A
5454958 Fiehler Oct 1995 A
5456693 Conston et al. Oct 1995 A
5456885 Coleman et al. Oct 1995 A
5474687 Van Vlasselaer Dec 1995 A
5486359 Caplan et al. Jan 1996 A
5494578 Brown et al. Feb 1996 A
5494592 Latham, Jr. et al. Feb 1996 A
5501371 Schwartz-Feldman Mar 1996 A
5505685 Antwiler Apr 1996 A
5510102 Cochrum Apr 1996 A
5520885 Coelho et al. May 1996 A
5525477 Hassouna Jun 1996 A
5533518 Vogler Jul 1996 A
5560830 Coleman et al. Oct 1996 A
5575778 Hardt et al. Nov 1996 A
5577513 Van Vlasselaer Nov 1996 A
5585007 Antanavich et al. Dec 1996 A
5588958 Cunningham et al. Dec 1996 A
5589462 Patat et al. Dec 1996 A
5601727 Bormann et al. Feb 1997 A
5603845 Holm Feb 1997 A
5607579 Latham, Jr. et al. Mar 1997 A
5614106 Payrat et al. Mar 1997 A
5618663 Delmas et al. Apr 1997 A
5632895 Tsukagoshi et al. May 1997 A
5632905 Haynes May 1997 A
5641414 Brown Jun 1997 A
5641622 Lake et al. Jun 1997 A
5643192 Hirsh et al. Jul 1997 A
5645540 Henniges et al. Jul 1997 A
5646004 Van Vlasselaer Jul 1997 A
5648223 Van Vlasselaer Jul 1997 A
5649903 Deniega et al. Jul 1997 A
5663051 Vlasselaer Sep 1997 A
5674173 Hlavinka et al. Oct 1997 A
5707331 Wells et al. Jan 1998 A
5707647 Dunn et al. Jan 1998 A
5707876 Levine Jan 1998 A
5716616 Prockop et al. Feb 1998 A
5723331 Tubo et al. Mar 1998 A
5724988 Dennehey et al. Mar 1998 A
5733466 Benebo et al. Mar 1998 A
5733545 Hood, III Mar 1998 A
5736033 Coleman et al. Apr 1998 A
5738784 Holm et al. Apr 1998 A
5738796 Bormann et al. Apr 1998 A
5750025 Holmes et al. May 1998 A
5750658 Coelho et al. May 1998 A
5762798 Wenthold et al. Jun 1998 A
5785700 Olson Jul 1998 A
5786217 Tubo et al. Jul 1998 A
5788662 Antanavich et al. Aug 1998 A
5792344 Holm Aug 1998 A
5795489 Holm et al. Aug 1998 A
5795571 Cederholm-Williams et al. Aug 1998 A
5795751 Apel Aug 1998 A
5811094 Caplan et al. Sep 1998 A
5811151 Hendriks et al. Sep 1998 A
5817519 Zelmanovic et al. Oct 1998 A
5823986 Peterson Oct 1998 A
5824084 Muschler Oct 1998 A
5830359 Knight et al. Nov 1998 A
5833866 Brown Nov 1998 A
5834418 Brazeau et al. Nov 1998 A
5837150 Langley et al. Nov 1998 A
5840502 Van Vlasselaer Nov 1998 A
5860937 Cohen Jan 1999 A
5863892 Stern et al. Jan 1999 A
5865785 Bischof Feb 1999 A
5885239 Headley et al. Mar 1999 A
5889584 Wardlaw Mar 1999 A
5895346 Wells et al. Apr 1999 A
5899874 Jonsson et al. May 1999 A
5900245 Sawhney et al. May 1999 A
5906934 Grande et al. May 1999 A
5916557 Berlowitz-Tarrant et al. Jun 1999 A
5916743 Lake et al. Jun 1999 A
5918622 Perez et al. Jul 1999 A
5924972 Turvaville et al. Jul 1999 A
5934803 Hutter Aug 1999 A
5938621 Kelly et al. Aug 1999 A
5955032 Kelly et al. Sep 1999 A
5955436 Kunkle, Jr. Sep 1999 A
5958250 Brown et al. Sep 1999 A
5958253 Holm et al. Sep 1999 A
5980734 Itoh et al. Nov 1999 A
5985315 Patat et al. Nov 1999 A
6007811 Sawyer et al. Dec 1999 A
6010627 Hood, III Jan 2000 A
6020196 Hu et al. Feb 2000 A
6022306 Dumont et al. Feb 2000 A
6025201 Zelmanovic et al. Feb 2000 A
6027655 Holm Feb 2000 A
6049026 Muschler Apr 2000 A
6051146 Green et al. Apr 2000 A
6051147 Bischof Apr 2000 A
6053856 Hlavinka Apr 2000 A
6054122 MacPhee et al. Apr 2000 A
6063297 Antanavich et al. May 2000 A
6063624 Kandler et al. May 2000 A
6071421 Brown Jun 2000 A
6071422 Hlavinka et al. Jun 2000 A
6071423 Brown et al. Jun 2000 A
6090793 Zimmermann et al. Jul 2000 A
6096309 Prior et al. Aug 2000 A
6117425 MacPhee et al. Sep 2000 A
6123655 Fell et al. Sep 2000 A
6150163 McPherson et al. Nov 2000 A
6153113 Goodrich et al. Nov 2000 A
6183737 Zaleske et al. Feb 2001 B1
6196987 Holmes et al. Mar 2001 B1
6197325 MacPhee et al. Mar 2001 B1
6200287 Keller et al. Mar 2001 B1
6200606 Peterson et al. Mar 2001 B1
6214338 Antanavich et al. Apr 2001 B1
6221315 Giesler et al. Apr 2001 B1
6245900 Yamasaki et al. Jun 2001 B1
6264890 Boehringer et al. Jul 2001 B1
6274090 Coelho et al. Aug 2001 B1
6277961 Hock et al. Aug 2001 B1
6280400 Niermann Aug 2001 B1
6296602 Headley Oct 2001 B1
6316247 Katz et al. Nov 2001 B1
6322785 Landesberg et al. Nov 2001 B1
6327491 Franklin et al. Dec 2001 B1
6328765 Hardwick et al. Dec 2001 B1
6342157 Hood, III Jan 2002 B1
6351659 Vilsmeier Feb 2002 B1
6355239 Bruder et al. Mar 2002 B1
6368298 Beretta et al. Apr 2002 B1
6368498 Guilmette Apr 2002 B1
6398972 Blasetti et al. Jun 2002 B1
6406671 DiCesare et al. Jun 2002 B1
6410344 Chung et al. Jun 2002 B1
6417004 Brady et al. Jul 2002 B1
6440444 Boyce et al. Aug 2002 B2
6444228 Baugh et al. Sep 2002 B1
6464624 Pages Oct 2002 B2
6471069 Lin et al. Oct 2002 B2
6472162 Coelho et al. Oct 2002 B1
6508778 Verkaart et al. Jan 2003 B1
6516953 DiCesare et al. Feb 2003 B1
6523698 Dennehey et al. Feb 2003 B1
6544162 Van Wie et al. Apr 2003 B1
6544727 Hei Apr 2003 B1
6558341 Swisher May 2003 B1
6596180 Baugh et al. Jul 2003 B2
6623959 Harris Sep 2003 B2
6629919 Egozy et al. Oct 2003 B2
6638503 Chitte et al. Oct 2003 B2
6676629 Andrew et al. Jan 2004 B2
6719901 Dolecek et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6758978 Bedell Jul 2004 B1
6777231 Katz et al. Aug 2004 B1
6803022 DiCesare et al. Oct 2004 B2
6811777 Mishra Nov 2004 B2
6830762 Baugh et al. Dec 2004 B2
6835353 Smith et al. Dec 2004 B2
6835377 Goldberg et al. Dec 2004 B2
RE38730 Wells et al. Apr 2005 E
6899813 Dolecek et al. May 2005 B2
6905612 Dorian et al. Jun 2005 B2
6911202 Amir et al. Jun 2005 B2
RE38757 Wells et al. Jul 2005 E
7011644 Andrew et al. Mar 2006 B1
7077273 Ellsworth et al. Jul 2006 B2
7077827 Greenfield Jul 2006 B2
7155288 Soykan et al. Dec 2006 B2
7179391 Leach et al. Feb 2007 B2
7195606 Ballin Mar 2007 B2
7223346 Dorian et al. May 2007 B2
7273886 Olivero et al. Sep 2007 B2
7354515 Coull et al. Apr 2008 B2
7374678 Leach et al. May 2008 B2
7411006 Shanbrom Aug 2008 B2
7470371 Dorian et al. Dec 2008 B2
7531355 Rodriguez et al. May 2009 B2
7553413 Dorian et al. Jun 2009 B2
7845499 Higgins et al. Dec 2010 B2
7914689 Higgins et al. Mar 2011 B2
8048321 Leach et al. Nov 2011 B2
8062534 Higgins et al. Nov 2011 B2
20010009757 Bischof et al. Jul 2001 A1
20020035820 Farris Mar 2002 A1
20020076400 Katz et al. Jun 2002 A1
20020082220 Hoemann et al. Jun 2002 A1
20020090711 Karlsson Jul 2002 A1
20020104808 Blasetti et al. Aug 2002 A1
20020114775 Pathak Aug 2002 A1
20020161449 Muschler Oct 2002 A1
20020169408 Beretta et al. Nov 2002 A1
20020172666 Sacchi et al. Nov 2002 A1
20020182664 Dolecek et al. Dec 2002 A1
20020192632 Hei et al. Dec 2002 A1
20030033021 Plouhar et al. Feb 2003 A1
20030033022 Plouhar et al. Feb 2003 A1
20030050709 Noth et al. Mar 2003 A1
20030050710 Petersen et al. Mar 2003 A1
20030082152 Hedrick et al. May 2003 A1
20030185803 Kadiyala et al. Oct 2003 A1
20030191429 Andrew et al. Oct 2003 A1
20030205538 Dorian et al. Nov 2003 A1
20040013575 Stevens et al. Jan 2004 A1
20040120942 McGinnis et al. Jun 2004 A1
20040171146 Katz et al. Sep 2004 A1
20040182395 Brookman Sep 2004 A1
20040182788 Dorian et al. Sep 2004 A1
20040182795 Dorian et al. Sep 2004 A1
20040251217 Leach et al. Dec 2004 A1
20050076396 Katz et al. Apr 2005 A1
20050084961 Hedrick et al. Apr 2005 A1
20050084962 Simon Apr 2005 A1
20050109716 Leach et al. May 2005 A1
20050130301 McKay et al. Jun 2005 A1
20050153441 Hedrick et al. Jul 2005 A1
20050153442 Katz et al. Jul 2005 A1
20050186120 Dorian et al. Aug 2005 A1
20050196393 Shanbrom Sep 2005 A1
20050196874 Dorian et al. Sep 2005 A1
20050247715 Ellsworth et al. Nov 2005 A1
20050260174 Fraser et al. Nov 2005 A1
20050260175 Hedrick et al. Nov 2005 A1
20050282275 Katz et al. Dec 2005 A1
20060051865 Higgins et al. Mar 2006 A1
20060057693 Simon Mar 2006 A1
20060083720 Fraser et al. Apr 2006 A1
20060140923 Evangelista et al. Jun 2006 A1
20060151384 Ellsworth et al. Jul 2006 A1
20060175242 Dorian et al. Aug 2006 A1
20060175244 Dorian et al. Aug 2006 A1
20060178610 Nowakowski Aug 2006 A1
20060196885 Leach et al. Sep 2006 A1
20060243676 Swift et al. Nov 2006 A1
20060273049 Leach et al. Dec 2006 A1
20060273050 Higgins et al. Dec 2006 A1
20060278588 Woodell-May Dec 2006 A1
20070034579 Dorian et al. Feb 2007 A1
20070036768 Fraser et al. Feb 2007 A1
20070075016 Leach Apr 2007 A1
20070208321 Leach et al. Sep 2007 A1
20080011684 Dorian et al. Jan 2008 A1
20080164204 Hatamian et al. Jul 2008 A1
20080173593 Coull et al. Jul 2008 A1
20080193424 McKale et al. Aug 2008 A1
20080210645 Coull et al. Sep 2008 A1
20080217263 Higgins et al. Sep 2008 A1
20080217264 Leach et al. Sep 2008 A1
20080217265 Leach et al. Sep 2008 A1
20080268064 Woodell-May Oct 2008 A1
20080269762 Simon et al. Oct 2008 A1
20080283474 Leach et al. Nov 2008 A1
20080306431 Yoo Dec 2008 A1
20090014391 Leach et al. Jan 2009 A1
20090018313 Shanbrom Jan 2009 A1
20090101599 Dorian et al. Apr 2009 A1
20090192528 Higgins et al. Jul 2009 A1
20090220482 Higgins et al. Sep 2009 A1
20090221075 Dorian et al. Sep 2009 A1
20090236297 Dorian et al. Sep 2009 A1
20090250413 Hoeppner Oct 2009 A1
20090253566 Chavarria Oct 2009 A1
20100055087 Higgins et al. Mar 2010 A1
20100140182 Chapman et al. Jun 2010 A1
20100206798 Dorian et al. Aug 2010 A1
20100256595 Leach et al. Oct 2010 A1
20100323870 Leach et al. Dec 2010 A1
20100324450 Leach et al. Dec 2010 A1
20110014705 Leach et al. Jan 2011 A1
20110020196 Grippi et al. Jan 2011 A1
20110021334 Leach et al. Jan 2011 A1
20110036786 Ellsworth Feb 2011 A1
20110056893 Leach et al. Mar 2011 A1
20110065183 Dorian et al. Mar 2011 A1
20110077596 Higgins et al. Mar 2011 A1
20110168193 Leach et al. Jul 2011 A1
20110192804 Landrigan et al. Aug 2011 A1
20110251041 Chavarria et al. Oct 2011 A1
20120015796 Leach et al. Jan 2012 A1
Foreign Referenced Citations (69)
Number Date Country
696278 Jan 1999 AU
9103724 Mar 1993 BR
1321138 Aug 1993 CA
2182862 Jun 1996 CA
2448415 Dec 2002 CA
1074709 Jul 1993 CN
56103 Oct 1860 DE
1443359 Nov 1968 DE
4202667 May 1993 DE
090997 Oct 1983 EP
0102773 Mar 1984 EP
0109374 May 1984 EP
0142339 May 1985 EP
0244834 Nov 1987 EP
0253198 Jan 1988 EP
0295771 Dec 1988 EP
0417818 Mar 1991 EP
534178 Mar 1993 EP
0534178 Mar 1993 EP
0592242 Apr 1994 EP
1005910 Jun 2000 EP
1006360 Jun 2000 EP
1289618 Mar 2003 EP
1406492 Apr 2004 EP
1427279 Jun 2004 EP
1467746 Oct 2004 EP
1509326 Mar 2005 EP
1670315 Jun 2006 EP
1716901 Nov 2006 EP
854715 Nov 1960 GB
60-053845 Mar 1985 JP
60250014 Dec 1985 JP
2036872 Feb 1990 JP
02071747 Mar 1990 JP
02129224 Oct 2000 JP
2004-305439 Nov 2004 JP
200598704 Apr 2005 JP
2005098704 Apr 2005 JP
2005524451 Aug 2005 JP
2006-305365 Nov 2006 JP
WO-8400905 Mar 1984 WO
WO-8802259 Apr 1988 WO
WO-9010031 Sep 1990 WO
WO-9222312 Dec 1992 WO
WO-9305067 Mar 1993 WO
WO-9308904 May 1993 WO
WO-9407548 Apr 1994 WO
WO-9617871 Jun 1996 WO
WO-9617871 Jun 1996 WO
WO-9848938 Nov 1998 WO
WO-0061256 Oct 2000 WO
WO-0074713 Dec 2000 WO
WO-0103756 Jan 2001 WO
WO-0183068 Nov 2001 WO
WO-0238610 May 2002 WO
WO-02060925 Aug 2002 WO
WO-02098566 Dec 2002 WO
WO-03015800 Feb 2003 WO
WO-03024215 Mar 2003 WO
WO-03053362 Jul 2003 WO
WO-03088905 Oct 2003 WO
WO-03092894 Nov 2003 WO
WO-03099412 Dec 2003 WO
WO-2004009207 Jan 2004 WO
WO-2004104553 Dec 2004 WO
WO-2005034843 Apr 2005 WO
WO-2007127834 Nov 2007 WO
WO-2007142908 Dec 2007 WO
WO-2009021257 Feb 2009 WO
Non-Patent Literature Citations (159)
Entry
“Caps for Corning® and Costar® Plastic Labware,” Technical Bulletin. (Dec. 2008) Corning, Incorporated.
“Cell Isolation Techniques, Methods and Materials, Working with Enzymes,” (2004) (9 pages) Worthington Biochemical Corp.
“Cell Isolation Theory, Tissue Types,” (2004) (5 pages) Worthington Biochemical Corp.
“Centrifuge Tubes” Corning Costar brochure. 1996/1997 Catalog pp. 76-77.
“Clotalyst® Autologous Clotting Factor” brochure. (Aug. 15, 2008) Biomet Biologics.
“Clotalyst® Autologous Clotting Factor. Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Brochure. Biomet Biologics (Aug. 15, 2008).
“Corning® 15 and 50 mL Centrifuge Tubes,” Life Sciences. (Jun. 2005) Corning Incorporated.
“Cytori Celution Cell Concentrate Device,” Exhibit 14, 510(k) Summary, FDA approval K060482 (Sep. 28, 2006).
“Frequently Asked Questions, 1. Kits, 2. Engzymes,” (2003) 3 pages Worthington Biochemical Corp.
“Letter CryoSeal FS System. Vaccines, Blood & Biologics,” letter. (Jul. 26, 2007) FDA U.S. Food and Drug Administation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm091631.htm (Web accessed Aug. 12, 2011).
“MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study” brochure. Web. Jul. 2, 2009 http://www.biomet.com/patients/clinical—recruitment—padstudy.cfm.
“MarrowStim™ Concentration System,” brochure. Biomet Biologics Jun. 15, 2008.
“Plasmax® Plasma Concentration System” brochure. (Jun. 15, 2008) Biomet® Biologics.
“Prosys PRP Kit,” brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit--5467051—5467061.html Printed from Web Aug. 24, 2011.
“Prosys PRP Kit,” Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web Jul. 18, 2011.
“ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc.,” PR Newslink: http:/tinyurl.com/4h3up. (Apr. 5, 2005) http://www.noblood.org/press-releases/2128-thermogenesis-corp-supply-autologous-thrombin-kits-biomet-inc [web accessed Sep. 27, 2011].
“Trypsinizing cells.” Bart's Cookbook, Web. Apr. 14, 2010. http://pingu.salk.edu/˜sefton/Hyper—protocols/trypsin.html.
Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., “An Anaphylactic Reaction to Topical Fibrin Glue”.
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”.
Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., “Intraoperative Procurement of Autologous Fibrin Glue”.
Badiavas, et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells,” (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003).
Bang, N.U., et al., “Plasma Protein Requirements for Human Platelet Aggregation” Ann. N.Y. Acad Sci, 201:280-299 (1972).
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31:3 (1991): 408-11.
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg 105: 5 (1993): 892-7.
BioCUE™ Platelet Concentration System, Dec. 2010. (2 pages).
Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”.
Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days.” Vox Sanq, vol. 68: 82-89, Feb. 1995.
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Crafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866.
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32:7 (1992): 641-3.
CLOTALYST™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostatis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages).
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May 1976).
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (Apr. 1995).
Connolly, John, M.D., et al. “Development of an Osteogenic Bone-Marrow Preparation.” The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691.
Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination,” Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888.
De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow,” Cells Tissues Organs 174:101-109 (2003).
De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow,” Immunology Letters 89:267-270 (2003).
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100:2 (Aug. 1990): 281-6.
DePalma, L., et al., “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods.” Transfusion (1993) vol. 33, No. 9; pp. 717-720.
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regeneration,” (Feb. 2003) pp. 215-219, Lippincott Williams & Wilkins, Inc.
DiMuzio, Paul et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells,” Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc.
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”.
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., vol. Philadelphia: W.B. Saunders Company, 1992.
Eppley, et al., “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004).
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhinol Laryngol 95 (May 25-26, 1985) 40-5.
Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (Aug. 15, 1975): 495-501.
Floryan, K. et al. “Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674.
Frasier, John K., et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37.
Friesen, M.D., Robert, et al. “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass.” Anesth. Analg 1993: 77-702-7.
Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches,” Pathol Biol (Paris), 53(10), Dec. 2005.
Gibble, J. W. and P. M. Ness. “Fibrin glue: The perfect operative sealant?” Transfusion 30 (1990): 741-7.
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (May 11, 2007) pp. 1249-1260, American Heart Association, Inc.
Gomillion, Cheryl T., et al., “Stem cells and adipose tissue engineering,” Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier.
GPS® III System, GPS® III Platelet Separation System, Leadership through Technology , brochure, Jul. 2007 (8 sheets).
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (Feb. 29, 2004) (9 pages).
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages.
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages.
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS® II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells,” Stem Cells: Concise Review, 22, Jan. 2004.
Guilak, Frank, et al., “Adipose-derived adult stem cells for cartilage tissue engineering,” Biorheology 41 (2004) pp. 389-399, IOS Press.
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69.
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (Mar. 1992): 357-9.
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use” (date unknown).
Harvest Technologies brochure, SmartPrep2 (2002).
Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source,” Cells Tissues Organs (2004) 178:2-12 Karger.
Haynesworth, S.E. et al. “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate” 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002).
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surg 23 (Sep. 1992): 640.
Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells,” Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005).
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003.
Hood, Andrew G., et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties,” (Jan. 1993) vol. 14 pp. 126-129.
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009.
International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
International Search Report and Written Opinion mailed Aug. 9, 2011 for PCT/US2011/031954 claiming benefit of U.S. Appl. No. 12/758,127, filed Apr. 12, 2010.
International Search Report and Written Opinion mailed Jul. 2, 2008 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008.
International Search Report and Written Opinion mailed Jul. 30, 2010 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Search Report and Written Opinion mailed Nov. 7, 2011 for PCT/US2011/045290 claiming benefit of U.S. Appl. No. 12/846,944, filed Jul. 30, 2010.
International Search Report and Written Opinion mailed Oct. 8, 2010 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
International Search Report for International Application No. PCT/US/0316506 mailed Oct. 13, 2003 which claims benefit of U.S. Appl. No. 60/383,013, filed May 24, 2002.
International Search Report for International Application No. PCT/US2007/012587 mailed Nov. 6, 2007 which claims benefit of U.S. Appl. No. 11/441,276, filed May 25, 2006.
Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration,” 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, 1 page (2006).
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (1980): 765-811).
Jayadev, Suprya. “Trypsinization of Adherent Cells.” Aug. 8, 1991. Web. Apr. 14, 2010 http://www.duke.edu/web/ceramide/protocols/0005.html.
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (Oct. 1999).
Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Aug. 2000.
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, Helene Matras, M.D., “Fibrin Seal: The State of the Art” (1985).
Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978).
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation o£ autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1992): 72-3.
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (1993): 543-4.
Kumar, Vijay et al. “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device,” Journal of American Society of Extra-Corporeal Technology. JECT: Mar. 2005:37; 390-395.
Kumar, Vijay et al. “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2007; 39:18-23.
Kumar, Vijay et al., “Autologous Thrombin: Intraoperative Production From Whole Blood.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2008; 40:94-98.
Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”.
Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., “Autologous Fibrin Tissue Adhesive”.
Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”.
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report,” Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery.
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (Feb. 1990): 165-81.
Longas, Maria O., “An Improved Method for the Purification of Human Fibrinogen.” J. Biochem (1980) vol. 11, pp. 559-564.
Lu, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair,” 19(1), Jan. 2002.
Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages. (REV Feb. 15, 2008).
Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix.” Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57.
Masri, Marwan A., et al. “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000.” Thromb Haemostas (Struttgart) (1983) vol. 49 (2); pp. 116-119.
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122:37 (1972): 517-523.
Minntech® Filtration Technologies Group, “Hemocor HPH® Hemoconcentrator,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages).
Minntech® Filtration Technologies Group, “Medical Applications: Blood Filtration” Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page).
Minntech® Filtration Technologies Group, “Renaflo® II Hemofilter,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages).
Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005).
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (Jul. 1986): 122-4.
Nakagami, Hironori, et al., “Novel Autologous Cell Tehrapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, (Dec. 2005) pp. 2542-2547, American Heart Association, Inc.
Nathan, Suresh,, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs,” The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986.
Notice of Allowance mailed Mar. 24, 2011 for U.S. Appl. No. 12/101,586.
Notice of Allowance mailed May 27, 2010 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008.
Notice of Allowance mailed Oct. 18, 2011 for U.S. Appl. No. 12/897,401.
Office Action (Final) mailed Mar. 18, 2010 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008.
Office Action mailed Feb. 3, 2011 for U.S. Appl. No. 12/101,586, filed Apr. 14, 2008.
Office Action mailed Nov. 16, 2010 for U.S. Appl. No. 12/897,401 claiming benefit of U.S. Appl. No. 12/101,594, filed Apr. 11, 2008.
Office Action mailed Oct. 16, 2009 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008.
Office Action mailed Sep. 20, 2010 for U.S. Appl. No. 12/101,586, filed Apr. 14, 2008.
Orphardt, Charles E., “Denaturation of Proteins,” Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurst.edu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011).
Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., “Surgical Tissue Adhesives in Otolaryngology—Head and Neck Surgery”.
Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd.
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (Feb. 6, 2004) pp. 223-229 American Heart Association, Inc.
Ponticiello, Michael S., “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc. (2006) 2 pages.
Rangappa, Sunil, M.D., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes,” Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg.
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1409-1422.
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1423-1424.
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (1992): 190 (1 page).
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eu r J Pediatr Surg 2 (1992): 285-6.
Schmidt, K.G., et al., “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, 23:97-106 (1979).
Schmidt, K.G., et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23:88-96 (1979).
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (Apr. 10, 2007) pp. 818-827 AlphaMed Press.
Semple, Elizabeth, PhD, et al. “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, A New Thrombin-Processing Device.” Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200.
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (Apr. 1993): 309-52.
Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc.
Silver, Frederick H., et al., “Review Preparation and use of fibrin glue in surgery.” Biomaterials 16 (1995) pp. 891-903.
Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery,” Scand J Thor Cardiovasc Surg 22:271-274, 1988.
Sutton, Robin G., et al. “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass.” Ann Thorac Surg (1993) vol. 56; pp. 941-943.
Swift, Mathew J., et al., “Characterization of Growth Factors in Platelet Rich Plasma,” 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Symphony II Platelet Concentrate System/PCS brochure; “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors,” DePuy (Jan. 2003).
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (Nov. 30, 2007) pp. 1-12, Elsevier Inc.
The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”.
The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”.
The Sports Medicine Center, “Knee Cartilage Implantation”, Carticel™, “Autologous Cultured Chondrocyte Implantation”, http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006).
The Stone Clinic, “Platelet Rich Plasma (PRP)”, web site printed May 2006.
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (1988): 381-9.
Weisman, MD., Robert A., “Biochemical Characterization of Autologous Fibrinogen Adhesive,” Laryngoscope 97: Oct. 1987; pp. 1186-1190.
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., vol. Philadelphia: W. B. Saunders Company, 1992.
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005).
Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
Yoon, Eulsik, M.D., Ph.D., et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model,” Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc.
Zhang, Duan-zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction,” Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China.
Zuk, Patricia A., Ph.D., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc.
Japan Office Action mailed Jan. 22, 2013 for Japan Application No. 2010-503066.
Related Publications (1)
Number Date Country
20120145652 A1 Jun 2012 US
Provisional Applications (1)
Number Date Country
60911407 Apr 2007 US
Divisions (1)
Number Date Country
Parent 12101594 Apr 2008 US
Child 12897401 US
Continuations (1)
Number Date Country
Parent 12897401 Oct 2010 US
Child 13400188 US